FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013044531> ?p ?o ?g. }

• W3013044531 abstract "Background. We investigated the association between TILs assessed by different metrics and clinical outcome (pathological complete response -pCR- and risk of recurrence) in the ETNA trial. Methods. In the ETNA study (NCT01822314) 695 patients with HER2-negative breast cancer (BC) were randomized to receive neoadjuvant paclitaxel or nab-paclitaxel followed by 4 cycles of an anthracycline regimen. In the ITT study population, the two treatments did not show significantly different rates of pCR nor different Event-Free Survival (EFS) (Gianni JAMA Oncol 2018, Gianni ASCO 2019). We measured TILs by optical evaluation on pre-treatment core biopsies using three different metrics: stromal and intratumoral TILs (sTILs, iTILs), and hotspot TILs (hTILs)ie. the field of highest TILs density, in order to capture some of the spatial heterogeneity of TILs reported as more informative in ER+ BCs (Heindl JNCI 2018). We then investigated the association of TILs with pCR and EFS separately in TN and in LuminalB-like (ER+ and/or PgR+, Ki67≥14%) groups, as well as possible treatment-biomarker interactions. Results. TILs could be assessed in 589 pts (85%). The three TILs metrics were significantly correlated (p 20%, n=126) TILs. In the low hTILs group, abraxane was significantly more effective than paclitaxel (HR 0.64 [0.26-0.89], p=0.02). In the high hTILs group, paclitaxel was associated with better long-term outcome (HR 3.79 [1.33-10.8], p=0.01). If the same cut-off was applied in TN BC, abraxane had a numerical trend for superiority compared to paclitaxel in the low hTILs tumors (HR 0.64 [0.34-1.20]). No differences were observed in the high TIL group. Conclusions. Pre-treatment assessment of TILs in the ETNA trial was predictive of the likelihood of pCR regardless of the tumor subtype, and was prognostic in the TN subgroup. The assessment of hotspot TILs seems to be more informative than average stromal TILs in LumB-like tumors. Finally, different levels of hTILs at baseline were associated with different benefit from abraxane compared to paclitaxel. This finding warrants independent confirmation, and the mechanism for the association is being investigated. Supported in part by an unrestricted grant from Celgene Sarl, Swizerland Citation Format: Giampaolo Bianchini, Chanel Smart, Mauro Mansutti, Antonio Anton, Luca Licata, Isabella Sassi, Lourdes Calvo, Giancarlo Bisagni, Begona Bermejo, Vladimir Semiglazov, Marc Thill, Jose Ignacio Chacon, Arlene Chan, Serafin Morales Murillo, Isabel Alvarez, Ainhara Lahuerta, Patrizia Zucchinelli, Claudio Doglioni, Giuseppe Viale, Pinuccia Valagussa, Ignasi Tusquet, Luca Gianni. Clinical implication of tumor infiltrating lymphocytes (TILs) in the ETNA study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD5-05." @default.
• W3013044531 created "2020-04-03" @default.
• W3013044531 creator A5002887246 @default.
• W3013044531 creator A5005769474 @default.
• W3013044531 creator A5008504309 @default.
• W3013044531 creator A5018922989 @default.
• W3013044531 creator A5022120066 @default.
• W3013044531 creator A5037733792 @default.
• W3013044531 creator A5045585552 @default.
• W3013044531 creator A5047380313 @default.
• W3013044531 creator A5048836858 @default.
• W3013044531 creator A5048969389 @default.
• W3013044531 creator A5050476736 @default.
• W3013044531 creator A5055136263 @default.
• W3013044531 creator A5058537459 @default.
• W3013044531 creator A5061761089 @default.
• W3013044531 creator A5065072315 @default.
• W3013044531 creator A5066650733 @default.
• W3013044531 creator A5068100907 @default.
• W3013044531 creator A5070770739 @default.
• W3013044531 creator A5075312632 @default.
• W3013044531 creator A5085797367 @default.
• W3013044531 creator A5089184178 @default.
• W3013044531 creator A5090790623 @default.
• W3013044531 date "2020-02-14" @default.
• W3013044531 modified "2023-10-14" @default.
• W3013044531 title "Abstract PD5-05: Clinical implication of tumor infiltrating lymphocytes (TILs) in the ETNA study" @default.
• W3013044531 doi "https://doi.org/10.1158/1538-7445.sabcs19-pd5-05" @default.
• W3013044531 hasPublicationYear "2020" @default.
• W3013044531 type Work @default.
• W3013044531 sameAs 3013044531 @default.
• W3013044531 citedByCount "0" @default.
• W3013044531 crossrefType "proceedings-article" @default.
• W3013044531 hasAuthorship W3013044531A5002887246 @default.
• W3013044531 hasAuthorship W3013044531A5005769474 @default.
• W3013044531 hasAuthorship W3013044531A5008504309 @default.
• W3013044531 hasAuthorship W3013044531A5018922989 @default.
• W3013044531 hasAuthorship W3013044531A5022120066 @default.
• W3013044531 hasAuthorship W3013044531A5037733792 @default.
• W3013044531 hasAuthorship W3013044531A5045585552 @default.
• W3013044531 hasAuthorship W3013044531A5047380313 @default.
• W3013044531 hasAuthorship W3013044531A5048836858 @default.
• W3013044531 hasAuthorship W3013044531A5048969389 @default.
• W3013044531 hasAuthorship W3013044531A5050476736 @default.
• W3013044531 hasAuthorship W3013044531A5055136263 @default.
• W3013044531 hasAuthorship W3013044531A5058537459 @default.
• W3013044531 hasAuthorship W3013044531A5061761089 @default.
• W3013044531 hasAuthorship W3013044531A5065072315 @default.
• W3013044531 hasAuthorship W3013044531A5066650733 @default.
• W3013044531 hasAuthorship W3013044531A5068100907 @default.
• W3013044531 hasAuthorship W3013044531A5070770739 @default.
• W3013044531 hasAuthorship W3013044531A5075312632 @default.
• W3013044531 hasAuthorship W3013044531A5085797367 @default.
• W3013044531 hasAuthorship W3013044531A5089184178 @default.
• W3013044531 hasAuthorship W3013044531A5090790623 @default.
• W3013044531 hasConcept C121608353 @default.
• W3013044531 hasConcept C126322002 @default.
• W3013044531 hasConcept C143998085 @default.
• W3013044531 hasConcept C2776694085 @default.
• W3013044531 hasConcept C2776802502 @default.
• W3013044531 hasConcept C2777292972 @default.
• W3013044531 hasConcept C2777511904 @default.
• W3013044531 hasConcept C2777701055 @default.
• W3013044531 hasConcept C2778326572 @default.
• W3013044531 hasConcept C2781413609 @default.
• W3013044531 hasConcept C2908647359 @default.
• W3013044531 hasConcept C530470458 @default.
• W3013044531 hasConcept C71924100 @default.
• W3013044531 hasConcept C99454951 @default.
• W3013044531 hasConceptScore W3013044531C121608353 @default.
• W3013044531 hasConceptScore W3013044531C126322002 @default.
• W3013044531 hasConceptScore W3013044531C143998085 @default.
• W3013044531 hasConceptScore W3013044531C2776694085 @default.
• W3013044531 hasConceptScore W3013044531C2776802502 @default.
• W3013044531 hasConceptScore W3013044531C2777292972 @default.
• W3013044531 hasConceptScore W3013044531C2777511904 @default.
• W3013044531 hasConceptScore W3013044531C2777701055 @default.
• W3013044531 hasConceptScore W3013044531C2778326572 @default.
• W3013044531 hasConceptScore W3013044531C2781413609 @default.
• W3013044531 hasConceptScore W3013044531C2908647359 @default.
• W3013044531 hasConceptScore W3013044531C530470458 @default.
• W3013044531 hasConceptScore W3013044531C71924100 @default.
• W3013044531 hasConceptScore W3013044531C99454951 @default.
• W3013044531 hasLocation W30130445311 @default.
• W3013044531 hasOpenAccess W3013044531 @default.
• W3013044531 hasPrimaryLocation W30130445311 @default.
• W3013044531 hasRelatedWork W10233532 @default.
• W3013044531 hasRelatedWork W11047152 @default.
• W3013044531 hasRelatedWork W13328401 @default.
• W3013044531 hasRelatedWork W14333088 @default.
• W3013044531 hasRelatedWork W16909223 @default.
• W3013044531 hasRelatedWork W1722690 @default.
• W3013044531 hasRelatedWork W1852032 @default.
• W3013044531 hasRelatedWork W2337926 @default.
• W3013044531 hasRelatedWork W5038423 @default.
• W3013044531 hasRelatedWork W8188359 @default.
• W3013044531 isParatext "false" @default.
• W3013044531 isRetracted "false" @default.
• W3013044531 magId "3013044531" @default.
• W3013044531 workType "article" @default.